欧盟最高药物小组建议批准Ojemda 用于患有罕见、难以治疗的脑肿瘤的孩子。 The EU's top drug panel recommends approval of Ojemda for kids with a rare, hard-to-treat brain tumor.

欧洲医药署的人类医疗产品委员会(CHMP)已发表积极意见,建议批准Ojemda(dabrafenib)作为针对复发或复发的BRAF改性小儿科低年级性微瘤儿童的独立治疗。 The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ojemda® (dabrafenib) as a standalone treatment for children with relapsed or refractory BRAF-altered pediatric low-grade glioma. 建议为患有这种稀有脑肿瘤的年轻病人提供了一个潜在的新选择,有待欧洲联盟委员会最后批准。 The recommendation marks a potential new option for young patients with this rare brain tumor, pending final approval by the European Commission.